Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Streptococcal Infections | 11 | 2023 | 184 | 1.340 |
Why?
|
| Streptococcus agalactiae | 13 | 2023 | 202 | 1.140 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2021 | 324 | 1.050 |
Why?
|
| Neonatal Sepsis | 2 | 2022 | 29 | 0.920 |
Why?
|
| Infant, Newborn | 24 | 2024 | 1479 | 0.840 |
Why?
|
| Contact Tracing | 3 | 2020 | 48 | 0.820 |
Why?
|
| Antibodies, Bacterial | 7 | 2021 | 153 | 0.780 |
Why?
|
| Infant | 24 | 2024 | 2244 | 0.760 |
Why?
|
| Patient Discharge | 1 | 2021 | 27 | 0.740 |
Why?
|
| Bacteria | 1 | 2021 | 47 | 0.730 |
Why?
|
| Tuberculosis | 5 | 2020 | 543 | 0.730 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2020 | 6 | 0.700 |
Why?
|
| Pediatrics | 1 | 2020 | 17 | 0.690 |
Why?
|
| Humans | 40 | 2024 | 14537 | 0.670 |
Why?
|
| Female | 31 | 2024 | 9103 | 0.610 |
Why?
|
| South Africa | 24 | 2024 | 7596 | 0.600 |
Why?
|
| Tuberculin Test | 3 | 2020 | 49 | 0.540 |
Why?
|
| HIV Infections | 11 | 2020 | 5097 | 0.520 |
Why?
|
| Sepsis | 3 | 2022 | 102 | 0.520 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2021 | 329 | 0.500 |
Why?
|
| End Stage Liver Disease | 1 | 2014 | 5 | 0.480 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 6 | 0.480 |
Why?
|
| Caregivers | 1 | 2015 | 76 | 0.480 |
Why?
|
| Hospitals, Public | 1 | 2014 | 45 | 0.460 |
Why?
|
| Calcitriol | 1 | 2014 | 6 | 0.460 |
Why?
|
| Dermatologic Agents | 1 | 2014 | 6 | 0.460 |
Why?
|
| Zinc Sulfate | 1 | 2014 | 6 | 0.460 |
Why?
|
| Liver Transplantation | 1 | 2014 | 55 | 0.450 |
Why?
|
| Immunoglobulin G | 4 | 2023 | 231 | 0.440 |
Why?
|
| Child Mortality | 2 | 2024 | 96 | 0.440 |
Why?
|
| Male | 16 | 2024 | 6754 | 0.440 |
Why?
|
| Hospitalization | 3 | 2019 | 418 | 0.430 |
Why?
|
| Infant, Newborn, Diseases | 3 | 2022 | 73 | 0.430 |
Why?
|
| Meningitis, Bacterial | 3 | 2024 | 38 | 0.420 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2018 | 472 | 0.390 |
Why?
|
| Child, Preschool | 10 | 2024 | 1748 | 0.390 |
Why?
|
| Pregnancy | 15 | 2024 | 1862 | 0.370 |
Why?
|
| Pregnancy Complications, Infectious | 6 | 2020 | 529 | 0.330 |
Why?
|
| Child | 10 | 2024 | 2242 | 0.330 |
Why?
|
| HIV-1 | 5 | 2018 | 1260 | 0.320 |
Why?
|
| Isoniazid | 2 | 2020 | 110 | 0.300 |
Why?
|
| Nod2 Signaling Adaptor Protein | 1 | 2007 | 1 | 0.290 |
Why?
|
| Bacterial Capsules | 3 | 2015 | 33 | 0.270 |
Why?
|
| Standard of Care | 2 | 2024 | 30 | 0.270 |
Why?
|
| Retrospective Studies | 4 | 2022 | 799 | 0.250 |
Why?
|
| Meningitis | 2 | 2024 | 26 | 0.250 |
Why?
|
| Case-Control Studies | 7 | 2021 | 480 | 0.240 |
Why?
|
| Incidence | 3 | 2021 | 685 | 0.220 |
Why?
|
| Bronchiolitis | 1 | 2023 | 8 | 0.210 |
Why?
|
| Bronchiolitis, Viral | 1 | 2023 | 9 | 0.210 |
Why?
|
| Bronchopneumonia | 1 | 2023 | 11 | 0.210 |
Why?
|
| Zidovudine | 2 | 2018 | 59 | 0.210 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 30 | 0.210 |
Why?
|
| Bacterial Infections | 1 | 2023 | 54 | 0.210 |
Why?
|
| Infant Mortality | 2 | 2024 | 97 | 0.200 |
Why?
|
| Pneumonia, Bacterial | 1 | 2002 | 54 | 0.200 |
Why?
|
| Cause of Death | 4 | 2024 | 221 | 0.200 |
Why?
|
| C-Reactive Protein | 1 | 2002 | 96 | 0.200 |
Why?
|
| Developmental Disabilities | 1 | 2022 | 22 | 0.190 |
Why?
|
| Brain Diseases | 1 | 2022 | 24 | 0.190 |
Why?
|
| Pneumococcal Vaccines | 1 | 2024 | 278 | 0.190 |
Why?
|
| Nucleic Acids | 1 | 2021 | 7 | 0.190 |
Why?
|
| Anti-HIV Agents | 3 | 2018 | 1324 | 0.190 |
Why?
|
| Prospective Studies | 6 | 2019 | 1160 | 0.180 |
Why?
|
| Pneumonia, Viral | 1 | 2002 | 104 | 0.180 |
Why?
|
| Antitubercular Agents | 3 | 2020 | 322 | 0.180 |
Why?
|
| Disease Notification | 1 | 2020 | 14 | 0.180 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2002 | 195 | 0.180 |
Why?
|
| Coinfection | 1 | 2023 | 276 | 0.180 |
Why?
|
| Pediatricians | 1 | 2020 | 1 | 0.180 |
Why?
|
| Nevirapine | 2 | 2017 | 146 | 0.180 |
Why?
|
| Risk Factors | 6 | 2022 | 1475 | 0.170 |
Why?
|
| Child, Hospitalized | 2 | 2021 | 26 | 0.170 |
Why?
|
| Milk, Human | 1 | 2020 | 23 | 0.170 |
Why?
|
| Adult | 9 | 2021 | 5913 | 0.170 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 101 | 0.170 |
Why?
|
| Polysaccharides, Bacterial | 2 | 2016 | 35 | 0.170 |
Why?
|
| Latent Tuberculosis | 1 | 2020 | 45 | 0.170 |
Why?
|
| Family Characteristics | 2 | 2020 | 135 | 0.160 |
Why?
|
| Specimen Handling | 1 | 2019 | 105 | 0.160 |
Why?
|
| Diarrhea | 1 | 2019 | 76 | 0.160 |
Why?
|
| Rotavirus Vaccines | 1 | 2019 | 53 | 0.160 |
Why?
|
| Physicians | 1 | 2018 | 31 | 0.150 |
Why?
|
| Nurses | 1 | 2018 | 32 | 0.150 |
Why?
|
| Cost of Illness | 1 | 2019 | 167 | 0.150 |
Why?
|
| Bayes Theorem | 3 | 2023 | 81 | 0.140 |
Why?
|
| Streptococcal Vaccines | 1 | 2016 | 47 | 0.130 |
Why?
|
| Bacterial Vaccines | 1 | 2016 | 13 | 0.130 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 262 | 0.130 |
Why?
|
| Gestational Age | 3 | 2022 | 80 | 0.130 |
Why?
|
| Rifampin | 1 | 2017 | 197 | 0.130 |
Why?
|
| Antigens, Surface | 1 | 2015 | 11 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2015 | 14 | 0.120 |
Why?
|
| Organizational Innovation | 1 | 2014 | 8 | 0.120 |
Why?
|
| Tertiary Care Centers | 3 | 2020 | 80 | 0.120 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2015 | 40 | 0.120 |
Why?
|
| Government Programs | 1 | 2014 | 30 | 0.120 |
Why?
|
| Child Health Services | 1 | 2014 | 35 | 0.120 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 57 | 0.120 |
Why?
|
| Administration, Cutaneous | 1 | 2014 | 31 | 0.110 |
Why?
|
| Time Factors | 2 | 2014 | 507 | 0.110 |
Why?
|
| Mass Screening | 1 | 2015 | 245 | 0.110 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 188 | 0.110 |
Why?
|
| Africa South of the Sahara | 2 | 2024 | 353 | 0.110 |
Why?
|
| Adolescent | 4 | 2019 | 2985 | 0.110 |
Why?
|
| Hepatitis B | 1 | 2014 | 125 | 0.100 |
Why?
|
| Biomarkers | 3 | 2015 | 327 | 0.100 |
Why?
|
| Autopsy | 2 | 2024 | 140 | 0.090 |
Why?
|
| Serogroup | 2 | 2021 | 150 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 293 | 0.080 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2007 | 2 | 0.070 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2007 | 7 | 0.070 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 4 | 0.070 |
Why?
|
| Interleukin-4 | 1 | 2007 | 7 | 0.070 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2007 | 6 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 14 | 0.070 |
Why?
|
| Leukocytes | 1 | 2007 | 14 | 0.070 |
Why?
|
| Risk | 2 | 2019 | 87 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2007 | 32 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2007 | 44 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2007 | 60 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 77 | 0.070 |
Why?
|
| Mothers | 2 | 2018 | 195 | 0.060 |
Why?
|
| HIV | 2 | 2020 | 380 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2002 | 63 | 0.060 |
Why?
|
| Young Adult | 3 | 2018 | 2498 | 0.060 |
Why?
|
| Child Nutrition Disorders | 1 | 2024 | 13 | 0.060 |
Why?
|
| Malnutrition | 1 | 2024 | 56 | 0.060 |
Why?
|
| Baths | 1 | 2004 | 1 | 0.060 |
Why?
|
| Disinfectants | 1 | 2004 | 3 | 0.060 |
Why?
|
| Chlorhexidine | 1 | 2004 | 10 | 0.060 |
Why?
|
| Comorbidity | 1 | 2024 | 188 | 0.060 |
Why?
|
| Prevalence | 2 | 2020 | 1192 | 0.050 |
Why?
|
| Stillbirth | 1 | 2024 | 83 | 0.050 |
Why?
|
| Ribs | 1 | 2023 | 4 | 0.050 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2023 | 7 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2023 | 36 | 0.050 |
Why?
|
| ROC Curve | 1 | 2002 | 51 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2004 | 187 | 0.050 |
Why?
|
| Survivors | 1 | 2022 | 5 | 0.050 |
Why?
|
| Mozambique | 1 | 2022 | 55 | 0.050 |
Why?
|
| Bacteremia | 1 | 2002 | 79 | 0.050 |
Why?
|
| Tongue | 1 | 2021 | 5 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2002 | 102 | 0.050 |
Why?
|
| Hospitals, Teaching | 1 | 2020 | 21 | 0.050 |
Why?
|
| Foster Home Care | 1 | 2000 | 3 | 0.040 |
Why?
|
| Sputum | 1 | 2021 | 135 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 385 | 0.040 |
Why?
|
| Diagnosis | 1 | 2019 | 7 | 0.040 |
Why?
|
| Epidemiologic Studies | 1 | 2019 | 13 | 0.040 |
Why?
|
| Pregnancy Outcome | 1 | 2020 | 117 | 0.040 |
Why?
|
| Pregnant Women | 1 | 2020 | 89 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2000 | 118 | 0.040 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1999 | 2 | 0.040 |
Why?
|
| Myxoma | 1 | 1999 | 3 | 0.040 |
Why?
|
| Heart Atria | 1 | 1999 | 7 | 0.040 |
Why?
|
| Heart Neoplasms | 1 | 1999 | 5 | 0.040 |
Why?
|
| Counseling | 1 | 2000 | 143 | 0.040 |
Why?
|
| Middle Aged | 1 | 2007 | 3601 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2019 | 149 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2019 | 179 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2000 | 147 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2022 | 967 | 0.040 |
Why?
|
| Obstetrics | 1 | 2018 | 10 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2018 | 26 | 0.040 |
Why?
|
| Infant, Low Birth Weight | 1 | 2018 | 35 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2019 | 253 | 0.040 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 4 | 0.040 |
Why?
|
| Focus Groups | 1 | 2018 | 196 | 0.040 |
Why?
|
| Pre-Eclampsia | 1 | 2018 | 56 | 0.040 |
Why?
|
| Urban Population | 1 | 2019 | 257 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 1081 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2019 | 889 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 279 | 0.030 |
Why?
|
| Breast Feeding | 1 | 2017 | 120 | 0.030 |
Why?
|
| Fimbriae, Bacterial | 1 | 2015 | 10 | 0.030 |
Why?
|
| Adhesins, Bacterial | 1 | 2015 | 12 | 0.030 |
Why?
|
| Poverty | 1 | 2016 | 152 | 0.030 |
Why?
|
| Viral Load | 1 | 2019 | 819 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2015 | 32 | 0.030 |
Why?
|
| Immunologic Techniques | 1 | 2014 | 4 | 0.030 |
Why?
|
| Vaccination | 1 | 2016 | 365 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 48 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2015 | 325 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2015 | 1422 | 0.020 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2004 | 30 | 0.010 |
Why?
|
| Hygiene | 1 | 2004 | 23 | 0.010 |
Why?
|
| Postpartum Period | 1 | 2004 | 85 | 0.010 |
Why?
|
| Vagina | 1 | 2004 | 91 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 370 | 0.010 |
Why?
|
| Echocardiography | 1 | 1999 | 100 | 0.010 |
Why?
|
| Heart Failure | 1 | 1999 | 38 | 0.010 |
Why?
|